Canada

TALLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001

Lead Product(s): TA-A001

Therapeutic Area: Ophthalmology Product Name: TA-A001

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 07, 2020

Details:

Patent covers the chemical composition of SmartCelle polymers, their method of manufacture and their ability to form 20nm-30nm stable drug-loaded dynamic micelles in aqueous solution. SmartCelle formulations comprising a number of anti-inflammatory drugs are presented.

InMed Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

InMed Releases CBN Preclinical Results in Glaucoma

Lead Product(s): Cannabinol

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 27, 2020

Details:

Combination of CBN and elevated pressure, within the same time period, resulted in a high level of cell survival in a dose dependent fashion. CBN was superior to both CBD and THC under identical testing conditions.

InMed Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

InMed Files PCT Patent Application for Neuroprotection in Glaucoma

Lead Product(s): Cannabinol

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 12, 2020

Details:

With INM-088, an eye drop formulation of CBN, the Company is exploring the treatment for glaucoma, either as a prospective stand-alone or an adjunct therapy, and in other ocular diseases.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

TALLC

TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001

InMed Pharmaceuticals

InMed Releases CBN Preclinical Results in Glaucoma

InMed Pharmaceuticals

InMed Files PCT Patent Application for Neuroprotection in Glaucoma